LONDON, Jan 28 (Reuters) - European prices for some
off-patent cancer drugs have risen by more than 100 percent in
the past five years, with two cases of hikes exceeding 1,000
percent, according to data presented at a medical conference on
Saturday.
Read more
No comments:
Post a Comment